Radiopharmaceuticals-Nuclear Medicine Market Leading Companies 2023 - Advanced Accelerator Applications S.A., Bayer AG, Bracco Imaging S.p.A, Cardinal Health, Eli Lilly and Co

Global radiopharmaceuticals/nuclear medicine market report gives comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies radiopharmaceuticals//nuclear medicine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the radiopharmaceuticals/nuclear medicine market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.

Request sample copy at: http://www.reportsweb.com/inquiry&RW00011411940/sample

Key players profiles in the global Radiopharmaceuticals-Nuclear Medicine in Emerging Countries include:
-Advanced Accelerator Applications S.A. (France)
-Bayer AG (Germany)
-Bracco Imaging S.p.A (Italy)
-Cardinal Health, Inc. (U.S.)
-Eli Lilly and Co. (U.S.)
-GE Healthcare (U.S.)
-IBA Molecular Imaging (Belgium)
-Jubilant Life Sciences Ltd (India)
-Lantheus Medical Imaging, Inc. (U.S.)
-Mallinckrodt plc (Ireland)
-Navidea Biopharmaceutical (U.S.)
-Nordion, Inc. (Canada)
-Siemens Healthineers (Germany)

Global Radiopharmaceuticals/Nuclear Medicine Market:
Global radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. Market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radio therapeutic and diagnostic procedures across the globe.
Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe
The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted into increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radio immunotherapies expected to drive the overall market revenue growth over the forecast period

Have any query? Enquire about report at: http://www.reportsweb.com/inquiry&RW00011411940/buying

Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.

North America accounts for larger revenue share in global radiopharmaceuticals market
North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region

Read complete report at: http://www.reportsweb.com/global-radiopharmaceuticals-nuclear-medicine-market-and-forecast-2017-2023

About ReportsWeb:

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.